Enterome to Chair Panel at Forthcoming Microbiome R&D and Business Collaboration Forum in London, UK
Paris, France – 24 April 2014
ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, announces that Prof. Alessandra Cervino, the Company’s new Head of Discovery, will chair a panel entitled “Sequencing, Bioinformatics and Characterising the Microbiome” at the forthcoming Microbiome R&D and Business Collaboration Forum.
Enterome is a Silver Sponsor of this international event, which draws leading scientists, business developers and investors interested in Microbiome research, product development and commercialisation to learn about the progress of a wide range of projects in areas such as metabolic diseases, inflammatory bowel disease, infectious diseases, intestinal cancers and the gut microbiome / brain interaction. The conference will take place at the London Heathrow Marriott Hotel, London, UK on 28-29 April, 2014.
Enterome is pioneering the development of innovative disease management solutions based on a deep understanding of the gut microbiome. Understanding and modifying the changes that occur in the gut microbiome during disease and in response to therapeutic interventions represent an entirely new and untapped opportunity to impact medicine.
Initially Enterome is using its expertise and proprietary technologies to develop novel diagnostic products to support patient stratification, personalized therapies and the clinical development of new drugs for the treatment of microbiome-related diseases such as inflammatory bowel diseases and metabolic diseases (diabetes and obesity). Enterome’s unique Metagenotyping® process has allowed it to develop biomarkers for treatment response prediction, disease activity monitoring and as potential companion diagnostics.
The company was established in 2012 in Paris, France, and has raised €7.5m from leading venture capital investors (Seventure, Omnes Capital & Lundbeckfond Ventures) and two strategic investors (Danone & Shire).
Pierre Belichard, CEO
+33 1 75 77 27 87
David Dible / Mark Swallow, Citigate Dewe Rogerson
+44 207 282 2949 / +44 207 282 2948